UniSuper Management Pty Ltd Has $1.40 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

UniSuper Management Pty Ltd boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 307.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,158 shares of the company’s stock after purchasing an additional 9,931 shares during the period. UniSuper Management Pty Ltd’s holdings in Moderna were worth $1,402,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of MRNA. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna during the 4th quarter worth approximately $27,000. Cedar Wealth Management LLC raised its position in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares in the last quarter. Arlington Trust Co LLC lifted its stake in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in Moderna in the first quarter valued at $32,000. Finally, Rise Advisors LLC grew its position in shares of Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after acquiring an additional 286 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

Shares of MRNA traded down $1.25 during mid-day trading on Tuesday, hitting $121.25. 1,751,748 shares of the company’s stock were exchanged, compared to its average volume of 4,046,165. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The stock’s 50-day simple moving average is $135.25 and its 200-day simple moving average is $114.90. The firm has a market cap of $46.47 billion, a price-to-earnings ratio of -7.74 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.19 earnings per share. On average, equities research analysts expect that Moderna, Inc. will post -7.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MRNA shares. Royal Bank of Canada upped their price objective on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price target on shares of Moderna in a report on Thursday, June 27th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. UBS Group increased their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Finally, Oppenheimer raised their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $134.02.

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $108.32, for a total transaction of $1,624,800.00. Following the completion of the sale, the director now owns 2,041,931 shares of the company’s stock, valued at $221,181,965.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO James M. Mock sold 689 shares of Moderna stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares in the company, valued at approximately $859,486.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $108.32, for a total value of $1,624,800.00. Following the transaction, the director now directly owns 2,041,931 shares of the company’s stock, valued at approximately $221,181,965.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 396,239 shares of company stock worth $55,286,137. Company insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.